Watch the video above to hear Mike’s acceptance speech and learn more about his innovative contributions to lymphatic research.
In 2020, Mike Masters founded Celltaxis LLC to advance research into the lymphatic system and develop new therapeutic approaches for lymphatic diseases. Celltaxis LLC is a clinical-stage company developing Acebilustat, a potent immune system-modulating drug. Acebilustat for arm lymphedema (LE) will be investigated in a clinical trial at Stanford University, a LE&RN Comprehensive Center of Excellence, led by Dr. Stanley G. Rockson. Mike shares, "It's clear that there needs to be more basic research and clinical science focused on better treatments. This is what drives us forward, and we hope that our study in some way serves as a spark that helps ignite further awareness of the unmet need that so many people living with LE experience every day."
The Visionary Award recognizes a person who has significantly contributed to the future of lymphatics. Mike will be honored during the Global Virtual Run/Walk to Fight Lymphatic Diseases live broadcast on April 22 at 12:00 pm EST.
